胃癌研究的最新进展：从分子图谱到治疗策略

IF 51 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2022-11-07 DOI:10.1038/s41575-022-00703-w

Maria Alsina, Virginia Arrazubi, Marc Diez, Josep Tabernero

{"title":"胃癌研究的最新进展：从分子图谱到治疗策略","authors":"Maria Alsina, Virginia Arrazubi, Marc Diez, Josep Tabernero","doi":"10.1038/s41575-022-00703-w","DOIUrl":null,"url":null,"abstract":"Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients. Gastric and gastro-oesophageal cancer is a leading cause of cancer-related death worldwide with a poor prognosis. This Review provides a comprehensive overview of current treatment strategies set on a molecular basis, and discusses future therapeutic avenues.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"20 3","pages":"155-170"},"PeriodicalIF":51.0000,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"26","resultStr":"{\"title\":\"Current developments in gastric cancer: from molecular profiling to treatment strategy\",\"authors\":\"Maria Alsina, Virginia Arrazubi, Marc Diez, Josep Tabernero\",\"doi\":\"10.1038/s41575-022-00703-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients. Gastric and gastro-oesophageal cancer is a leading cause of cancer-related death worldwide with a poor prognosis. This Review provides a comprehensive overview of current treatment strategies set on a molecular basis, and discusses future therapeutic avenues.\",\"PeriodicalId\":18793,\"journal\":{\"name\":\"Nature Reviews Gastroenterology &Hepatology\",\"volume\":\"20 3\",\"pages\":\"155-170\"},\"PeriodicalIF\":51.0000,\"publicationDate\":\"2022-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Gastroenterology &Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41575-022-00703-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Gastroenterology &Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41575-022-00703-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 26

摘要

胃癌和胃食管交界癌是全球医疗保健领域的一大挑战。尽管化疗和手术方案的疗效有所改善，但这些患者的预后仍然很差。在晚期疾病中，只有曲妥珠单抗和一些免疫检查点抑制剂，如尼妥珠单抗和pembrolizumab，在化疗的基础上，分别对HER2阳性和PDL1阳性肿瘤患者显示出稳定可靠的疗效。在这篇综述中，我们从分子和临床角度讨论了胃癌和胃食管癌的内在特征，并全面回顾了之前报道的和正在进行的晚期和局部靶向药物和免疫疗法的II期和III期临床试验。最后，我们提出了一些替代策略，以帮助克服当前精准医学面临的挑战，改善这些患者的预后。胃癌和胃食管癌是全球癌症相关死亡的主要原因，且预后较差。本综述全面概述了以分子为基础的当前治疗策略，并讨论了未来的治疗途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Current developments in gastric cancer: from molecular profiling to treatment strategy

查看原文本刊更多论文

Current developments in gastric cancer: from molecular profiling to treatment strategy

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients. Gastric and gastro-oesophageal cancer is a leading cause of cancer-related death worldwide with a poor prognosis. This Review provides a comprehensive overview of current treatment strategies set on a molecular basis, and discusses future therapeutic avenues.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.